Even when the FDA agrees to expanded access, pharmaceutical companies are often reluctant to give terminal patients a drug that is still in developme… - Mary Ruwart

" "

Even when the FDA agrees to expanded access, pharmaceutical companies are often reluctant to give terminal patients a drug that is still in development. If patients die from organ failure related to their disease, the FDA may require additional studies from the manufacturer to make sure that the death was not hurried along by the drug. Naturally, the extra studies increase the development timeline and overall cost.